Heart Institute Gathers for Grant Reviews and Policy Talks
Published Date: 9/11/2025
Notice
Summary
The National Heart, Lung, and Blood Institute is holding a public meeting on October 29, 2025, to discuss important health program policies and review grant applications. Researchers and organizations applying for funding will be affected, as some parts of the meeting will be private to protect sensitive information. Anyone interested can watch the open session online or even request to speak if they act fast!
Analyzed Economic Effects
5 provisions identified: 4 benefits, 1 costs, 0 mixed.
Open Session Is Webcast and Public
You can watch the open session of the National Heart, Lung, and Blood Advisory Council meeting online via the NHLBI videocast. The open session is on October 29, 2025 from 8:30 a.m. to 5:00 p.m., and registration is not required to attend the open portion in person.
Closed Session Protects Grant Applicant Data
A closed session will be held October 29, 2025 from 8:00 a.m. to 8:30 a.m. to review and evaluate grant applications. The closed session is to protect confidential trade secrets, patentable material, and personal information of applicants.
How to Request to Speak at Meeting
If you want to present oral comments, you must notify the Contact Person at least 10 days before the October 29, 2025 meeting and submit a letter of intent with a short description. Only one representative per organization may speak, presentations may be limited to five minutes, and printed and electronic copies are requested.
Written Comments May Be Submitted
Anyone may file written comments with the committee by sending a statement to the Contact Person. The statement should include your name, address, telephone number, and, if applicable, business or professional affiliation.
On-Campus Security and ID Rules for Visitors
Visitors attending the in-person meeting at NIH must follow NIH visitor security procedures, including showing one form of ID and having visitor vehicles inspected before campus entry. The NIH security procedures webpage provides details for entrance to on-campus and off-campus facilities.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14980, Government Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration
The National Eye Institute has a cool new invention using special peptides to help protect eyes from inherited diseases like retinitis pigmentosa, which causes vision loss for over 100,000 Americans. They’re looking for partners to help develop easy-to-use eyedrops or gene therapy to slow down or stop this eye damage. This could bring hope and new treatments to many people with few options, and interested parties can start talking to the NIH now!
Previous / Next Documents
Previous: 2025-17536, Advisory Committee on Cemeteries and Memorials, Notice of Meeting
The Department of Veterans Affairs is holding its annual Advisory Committee on Cemeteries and Memorials meeting on October 28-29, 2025, in Washington, DC. This meeting affects veterans and their families by discussing cemetery management, memorials, and burial benefits, with public input welcomed. No new costs are announced, but the committee’s recommendations could shape future veteran services.
Next: 2025-17539, Data Collection Available for Public Comments
The Small Business Administration wants to keep or update a form they use to collect info from small businesses. They’re asking the public to share thoughts on this for the next 60 days. This helps make sure the paperwork isn’t too much work and keeps things running smoothly without extra costs or delays.